Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study
Laham R, Chronos N, Pike M, Leimbach M, Udelson J, Pearlman J, Pettigrew R, Whitehouse MJ, Yoshizawa C, Simons M. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study. Journal Of The American College Of Cardiology 2000, 36: 2132-2139. PMID: 11127452, DOI: 10.1016/s0735-1097(00)00988-8.Peer-Reviewed Original ResearchConceptsIntracoronary basic fibroblast growth factorOpen-label dose-escalation studyDose-escalation studyIschemic heart diseaseBasic fibroblast growth factorFibroblast growth factorHeart diseaseGrowth factorPhase I open-label dose-escalation studyFGF-2Non-Q-wave myocardial infarctionSevere ischemic heart diseaseSeattle Angina QuestionnaireTreadmill exercise testingQuality of lifeRegional wall thickeningMagnetic resonance imagingRFGF-2Angina QuestionnaireExercise toleranceRetinal examinationEscalation studyExercise testingIntracoronary administrationLaboratory parametersTherapeutic Angiogenesis
Simons M, Laham R, Post M, Sellke F. Therapeutic Angiogenesis. BioDrugs 2000, 14: 13-20. PMID: 18034552, DOI: 10.2165/00063030-200014010-00002.Peer-Reviewed Original ResearchGrowth factorTherapeutic angiogenesisAdvanced coronary diseaseAdverse effect profileInitial clinical dataRecent clinical experienceBasic fibroblast growth factorQuality of lifeAngiogenic growth factorsFibroblast growth factorCoronary diseaseEffect profileClinical dataPreclinical studiesAnimal modelsClinical experienceNew vasculatureClinical applicationPractical clinical applicationsAngiogenesisBFGFBasic biologyPatientsFactorsSymptoms